Blog

Wafik S. El-Deiry: Keep up with drug names mentioned in the NEJM in the last month

Photo of Wafik El-Deiry from brown.edu

Aug 9, 2024, 13:35

Wafik S. El-Deiry: Keep up with drug names mentioned in the NEJM in the last month

Wafik S. El-Deiry shared on X:

“For my colleagues on MedTwitter trying to keep up with drug names, these were mentioned in the NEJM in the last month: Crinecerfont, Nipocalimab, Belantamab Mafodotin, Nirmatrelvir, Tirzepatide, Survodutide, Blinatumomab, Sotorasib, Semaglutide, Recombinant ADAMTS13, Tenecteplase, Risankizumab, Ustekinumab, Nirmatrelvir–Ritonavir, Efanesoctocog Alfa, Interleukin-23 p19, Interleukin-12 p40, Bioengineered Factor VIII, Felzartamab, Bulevirtide, Pegylated Interferon, Nirsevimab, Pembrolizumab, Donidalorsen, Sebetralstat, Tisotumab Vedotin.”

Source: Wafik S. El-Deiry/X

Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.

belantamab mafodotin Bioengineered Factor VIII blinatumomab Bulevirtide cancer Crinecerfont Donidalorsen Efanesoctocog Alfa Felzartamab Interleukin-12 p40 Interleukin-23 p19 NEJM nipocalimab Nirmatrelvir Nirmatrelvir–Ritonavir Nirsevimab OncoDaily Oncology Pegylated Interferon pembrolizumab Recombinant ADAMTS13 Risankizumab Sebetralstat semaglutide Sotorasib Survodutide Tenecteplase tirzepatide Tisotumab vedotin Ustekinumab Wafik S. El-Deiry

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage